MX2019001360A - Composiciones y metodos para el tratamiento de sindrome de intestino irritable. - Google Patents

Composiciones y metodos para el tratamiento de sindrome de intestino irritable.

Info

Publication number
MX2019001360A
MX2019001360A MX2019001360A MX2019001360A MX2019001360A MX 2019001360 A MX2019001360 A MX 2019001360A MX 2019001360 A MX2019001360 A MX 2019001360A MX 2019001360 A MX2019001360 A MX 2019001360A MX 2019001360 A MX2019001360 A MX 2019001360A
Authority
MX
Mexico
Prior art keywords
formula
compositions
treatment
bowel syndrome
irritable bowel
Prior art date
Application number
MX2019001360A
Other languages
English (en)
Inventor
Kandula Mahesh
Original Assignee
Cellix Bio Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cellix Bio Private Ltd filed Critical Cellix Bio Private Ltd
Publication of MX2019001360A publication Critical patent/MX2019001360A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • C07C233/53—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/55—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a carbon atom of an unsaturated carbon skeleton
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C15/00—Cyclic hydrocarbons containing only six-membered aromatic rings as cyclic parts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/52—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton
    • C07C229/54—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C229/60—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to carbon atoms of six-membered aromatic rings of the same carbon skeleton with amino and carboxyl groups bound to carbon atoms of the same non-condensed six-membered aromatic ring with amino and carboxyl groups bound in meta- or para- positions
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/14—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of carbon skeletons containing rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/12—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates

Abstract

Las descripciones aquí proporcionan compuestos de fórmula I, fórmula II, fórmula III, fórmula IV, fórmula V, fórmula VI, fórmula VII, fórmula VIII, fórmula IX, fórmula X, fórmula XI, fórmula XII, fórmula XIII, fórmula XIV y fórmula XV o sus sales farmacéuticamente aceptables, así como los polimorfos, enantiómeros, estereoisómeros, solvatos e hidratos de los mismos. Estas sales pueden formularse como composiciones farmacéuticas. Las composiciones farmacéuticas pueden formularse para administración oral, supositorio, transdérmica, bucal, rectal, tópica, transdérmica, transmucosa, intravenosa, parenteral, por jarabe o inyección. Dichas composiciones pueden usarse para el tratamiento del síndrome del intestino irritable (IBS), enfermedades inflamatorias del intestino o sus complicaciones asociadas.
MX2019001360A 2016-08-11 2017-04-19 Composiciones y metodos para el tratamiento de sindrome de intestino irritable. MX2019001360A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201641027529 2016-08-11
PCT/IB2017/052233 WO2018029545A1 (en) 2016-08-11 2017-04-19 Compositions and methods for the treatment of irritable bowel syndrome

Publications (1)

Publication Number Publication Date
MX2019001360A true MX2019001360A (es) 2019-06-03

Family

ID=61163212

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019001360A MX2019001360A (es) 2016-08-11 2017-04-19 Composiciones y metodos para el tratamiento de sindrome de intestino irritable.

Country Status (14)

Country Link
US (2) US11078154B2 (es)
EP (1) EP3481383B1 (es)
JP (1) JP2019524796A (es)
KR (1) KR20190039723A (es)
CN (1) CN109640965A (es)
AU (1) AU2017308801B2 (es)
CA (1) CA3031893A1 (es)
IL (1) IL264467B (es)
MX (1) MX2019001360A (es)
NZ (1) NZ750126A (es)
RU (1) RU2751770C2 (es)
SG (2) SG11201900588YA (es)
WO (1) WO2018029545A1 (es)
ZA (1) ZA201900466B (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20210174A1 (es) * 2018-02-02 2021-01-29 Boehringer Ingelheim Int Derivados de oxadiazolopiridina sustituidos con bencilo, (piridin-3-il)metilo o (piridin-4-il)metilo como inhibidores de ghrelin o-aciltransferasa (goat)
CN113398112A (zh) * 2021-06-17 2021-09-17 西南医科大学 FA介导的BBA/CM-β-CD靶向递药系统、制备方法及其应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080646A (en) 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
CN1044364C (zh) * 1993-06-26 1999-07-28 河南师范大学 一种治疗肠炎和溃疡性结肠炎的药物及其制备工艺
IL113459A (en) 1995-04-23 2000-07-16 Electromagnetic Bracing System Electrophoretic cuff apparatus
US6239180B1 (en) 1995-11-08 2001-05-29 The Regents Of The University Of California Transdermal therapeutic device and method with capsaicin and capsaicin analogs
CA2275539A1 (en) 1997-10-28 1999-05-06 Bando Chemical Industries, Ltd. A transdermal patch and a method for manufacture of a substrate sheet therefor
US6103275A (en) 1998-06-10 2000-08-15 Nitric Oxide Solutions Systems and methods for topical treatment with nitric oxide
DE19827732A1 (de) 1998-06-22 1999-12-23 Rottapharm Bv Transdermales System vom Matrix-Typ zur Abgabe von Wirkstoffen mit einer hohen Abgaberate von Steroid-Hormonen und die Verwendung eines derartigen Systems zur Hormonersatztherapie
US6312716B1 (en) 1999-05-10 2001-11-06 Peierce Management Llc Patch and method for transdermal delivery of bupropion base
US6974588B1 (en) 1999-12-07 2005-12-13 Elan Pharma International Limited Transdermal patch for delivering volatile liquid drugs
WO2006125293A1 (en) * 2005-05-27 2006-11-30 Antibe Therapeutics Inc. Derivatives of 4- or 5-aminosalicylic acid
EA018606B1 (ru) * 2006-01-05 2013-09-30 Велоксис Фармасьютикалз А/С Распадающиеся загружаемые таблетки
ES2656903T3 (es) * 2008-07-08 2018-02-28 Catabasis Pharmaceuticals, Inc. Salicilatos acetilados de ácidos grasos y sus usos
CN102421431B (zh) * 2009-04-06 2019-04-02 克雷勒内有限公司 包含一或多种肌酸化合物的血液透析和腹膜透析溶液
IT1400119B1 (it) * 2010-05-24 2013-05-17 Sofar Spa Nuovi derivati della mesalazina, processo di sintesi ed uso nel trattamento di malattie infiammatorie intestinali.
SG11201407319YA (en) * 2012-05-23 2014-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of inflammatory bowel disease
WO2014091384A2 (en) * 2012-12-12 2014-06-19 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease

Also Published As

Publication number Publication date
AU2017308801A1 (en) 2019-02-07
AU2017308801B2 (en) 2022-03-10
RU2751770C2 (ru) 2021-07-16
RU2019101849A (ru) 2020-09-11
NZ750126A (en) 2022-07-01
US11078154B2 (en) 2021-08-03
IL264467B (en) 2021-09-30
SG11201900588YA (en) 2019-02-27
EP3481383A1 (en) 2019-05-15
IL264467A (en) 2019-02-28
US20220162156A1 (en) 2022-05-26
US20190177267A1 (en) 2019-06-13
JP2019524796A (ja) 2019-09-05
EP3481383A4 (en) 2020-03-18
RU2019101849A3 (es) 2020-09-11
CA3031893A1 (en) 2018-02-15
WO2018029545A1 (en) 2018-02-15
CN109640965A (zh) 2019-04-16
KR20190039723A (ko) 2019-04-15
ZA201900466B (en) 2020-06-24
SG10202101247QA (en) 2021-03-30
EP3481383B1 (en) 2023-06-14

Similar Documents

Publication Publication Date Title
MX2019007713A (es) Composiciones y metodos para el tratamiento del dolor cronico.
NZ766570A (en) Pyrimidinones as factor xia inhibitors
MX2019003912A (es) Composiciones y métodos para el tratamiento de xerostomia (sequedad bucal).
JO3261B1 (ar) مشتق بيريدين أحادي الحلقة
MD20160118A2 (ro) Derivaţi ai pirolidin-2,5-dionei, compoziţii farmaceutice şi metode de utilizare ca inhibitori ai IDO1
WO2013175377A3 (en) Compositions and methods for treatment of mucositis
WO2016046680A3 (en) Compositions and methods for the treatment of liver metabolic diseases
WO2013175376A3 (en) Compositions and methods for the treatment of local pain
NZ701832A (en) Compositions and methods for treatment of inflammatory bowel disease
MX2019000279A (es) Composiciones y metodos para el tratamiento del cancer.
MX2022005523A (es) Composiciones y metodos para el tratamiento de infecciones fungicas.
WO2014141057A3 (en) Compositions and methods for the treatment of cancer
MX2019001360A (es) Composiciones y metodos para el tratamiento de sindrome de intestino irritable.
WO2014091384A3 (en) Compositions and methods for the treatment of mucositis
MX2019006163A (es) Composiciones y metodos para el tratamiento de enfermedades infecciosas orales.
WO2013175359A3 (en) Compositions and methods for the treatment of multiple sclerosis
WO2014068463A3 (en) Compositions and methods for the treatment of inflammation and metabolic disorders
WO2014087307A3 (en) Compositions and methods for the treatment of metabolic syndrome and diabetes
MX2019005568A (es) Composiciones y metodos para el tratamiento de polipos gastrointestinales.
WO2020075023A3 (en) Compositions and methods for the treatment of parkinson's disease
MX2015008661A (es) Proceso para la obtencion de un derivado de fluorlactona.
WO2014087323A3 (en) Compounds and compositions for the treatment of autoimmune and chronic metabolic diseases
WO2015028976A3 (en) Compounds and methods for the treatment of inflammatory diseases
SG10201906474QA (en) Compositions and methods for the treatment of mucositis
MX2021000740A (es) Composiciones y metodos para el tratamiento del cancer.